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Abstract  
BACKGROUND: Peripheral blood hematopoietic stem cells (PBSC) have largely replaced bone 
marrow derived stem cells in autologous transplantations, and have become the preferred source of 
stem cells in the majority of allogeneic transplantations. Sufficient number of mobilized and 
collected hematopoietic stem cells (HSC) is needed for successful hematopoietic stem cell 
transplantation.  
MATERIAL AND METHOD: This study was performed in the Institute for Transfusion Medicine of 
RM and the University Clinic of Hematology from 2008 till 2016. There were 30 allogeneic and 90 
autologous donors that underwent mobilization and collection of PBSC. The association between 
possible predictive factors such as demographic characteristics, laboratory parameters and 
collection parameters in both groups, and mobilization strategy and clinical characteristics in 
autologous donors and number of collected PBSC was analyzed.  
RESULTS: There were 226 apheresis, 182 in autologous donors (mean 2, range 1-3) and 44 
apheresis in 30 allogeneic donors (mean 1.5, range 1-2). The mean number of collected MNC in 
autologous donors was 3.09 x 10
8
/kg and 2.85 x 10
6
/kg CD34+ cells, and 3.23 x 10
8
/kg MNC and 
3.20 x 10
6
/kg CD34+ cells in allogeneic donors. Significantly larger number of MNC and CD34+ 
cells was collected with the WBC set. There was a statistically significant correlation between the 
total number of collected MNC in autologous donors and platelet count before mobilization, the 
number of cycles in one apheresis procedure, quantity of collected graft and the number of 
collected MNC and CD34+ cells on the first day of harvestration. There was a statistically significant 
correlation between the total number of collected MNC in allogeneic donors and platelet count 
before mobilization, the number of cycles in one apheresis procedure, quantity of collected graft 
and number of MNC on first day of harvestration. There was a strong correlation between the 
number of collected MNC and CD34+ cells on the first harvest and the total number of collected 
MNC and CD34+ cells in poor mobilizers, and inverse correlation with the number of apheresis 
procedures. Donors who donated MNC ≤ 0.7 x 10
8
/kg and/or ≤ 0.7 x 10
6
/kg CD34+ cells on the first 
harvest (84.6%) were strong predictors of poor mobilizers.  
CONCLUSION: Determining the proper level of baseline and preaheresis laboratory parameters for 
initiating mobilization and apheresis procedure which is safe for donors and greatly efficient in 
collection of PBSC is needed for optimization of these procedures, as well as for early intervention 
in poor mobilizers. 
 
Introduction 
 
Hematopoietic stem cells transplantation 
(HSCT) has been used as a curative treatment in 
variety of congenital and acquired hematological and 
non-hematological benign and malign diseases [1-8]. 
Transplantation of peripheral blood stem cells (PBSC) 
provides complete and long-term reconstitution of the 
hematopoietic system of the patients and may result 
in remission or cure in a proportion of cases [8-9]. 
Given the numerous advantages such as, lower rates 
of morbidity and mortality, shorter hospitalization, 
lower costs of treatment and the possibility of applying 
high-dose chemotherapy to an older group of patients, 
mobilized peripheral blood stem cells have largely 
replaced the use of bone marrow derived stem cells 
as the preferred source of hematopoietic stem cells in 
autologous and allogeneic transplantation [1, 4, 8-13]. 
There is no consensus on the amount of progenitor 
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cells to be infused to achieve adequate cell recovery 
yet. However, a minimum of 2-5×10
6
 CD34+ cells per 
kilogram in adults have shown good results [14, 15]. 
Worldwide 99% of autologous hematopoietic stem cell 
transplantations and 75% of allogeneic are performed 
with PBSC. Progenitor stem cells are rare and they 
primarily reside in the bone marrow and in extreme 
small amounts (0.01-0.5% nucleated cells) in the 
peripheral blood [16, 17].  
Mobilization of these cells in the peripheral 
blood with growth factors only or in combination with 
chemotherapy results in multiplying the number of 
circulating hematopoietic stem cells, makes it easier 
to be harvested from the peripheral blood [17, 18]. 
Proper timing of collection of PBSC following 
mobilization is crucial for maximization of harvest. 
Few different parameters were investigated as 
possible predictive factors for apheresis harvest, such 
as number of platelets [4, 19, 20], total leukocyte 
count [20], lymphocyte count [20], monocyte count 
(20,21) and percentage of circulating immature 
granulocytes [22]. Number of CD34+ cells in the 
peripheral blood is accepted as best indicator for 
initiation of apheresis. Although the technics used for 
calculating the number of CD34+ cells are highly 
specialized and expensive, they are not universally 
available and it takes longer to obtain results [20, 23-
27]. Therefore, parameters that are more available 
were investigated as potential predictive factors. It is 
still not clear which protocol is optimal for maximal 
harvesting of PBSC.  
The aim of this study is to analyze the 
association between the mobilized and collected 
PBSC and possible predictive factors, such as 
demographic characteristics, laboratory parameters 
and collection parameters in both autologous and 
allogeneic donors and the mobilization strategy and 
clinical characteristics in autologous donors. 
 
 
Material and Methods 
 
This is a retrospective-prospective study 
performed in the Institute for Transfusion Medicine of 
RM and the University Clinic of Hematology in Skopje, 
Macedonia from 2008 till 2016. The investigated 
group consisted of 90 autologous donors/hematologic 
patients - 30 patients diagnosed with acute myeloid 
leukemia (AML), 30 with lymphoma and 30 with 
multiple myeloma (MM), and 30 allogeneic donors. 
The study was approved by the Ethical Committee for 
Biomedical Research at Medical Faculty in Skopje. All 
subjects in the study gave their written consent for 
performing the research, mobilizing strategy, 
apheresis collection of peripheral blood hematopoietic 
stem cells, cryopreservation and transplantation 
(according to Recommendations of WMA Revision of 
Declaration of Helsinki). Mobilization of PBSC was 
performed with the granulocyte colony-stimulating 
factor (G-CSF) 10µcg/kg/day (as single mobilizing 
strategy) or in combination of G-CSF + chemotherapy 
depending on diagnosis and disease status. The 
collection of PBSC was performed by the apheresis 
procedure with the cellular separator COBE Spectra 
Version 6.1 (TerumoBCT) in the Institute for 
Transfusion Medicine of RM. Collection target was 
≥2x10
8
/kg MNC and/or ≥2x10
6
/kg CD34+ cells during 
the first three days of apheresis. The following 
parameters were analyzed: demographic 
characteristics, laboratory parameters and collection 
parameters in both autologous and allogeneic donors; 
and the mobilization strategy and clinical 
characteristics in autologous donors. 
Table 1: Characteristics of autologous and allogeneic donors 
Donors characteristics Autologous 
(Number / %) 
Allogeneic 
(Number / %) 
p < 0.05 
Gender    
Male 56 (62.2%) 21 (70.0%)  
Female 34 (37.8%) 9 (30.0%)  
Age     
(mean, range)  45±13.0 (18-65) 34.3±12.2 (19-63)  
< 20  3 (3.4%) 2 (6.7%)  
20-29 11 (12.2%) 12 (40.0%)  
30-39 15 (16.7%) 4 (13.3%)  
40-49 21 (23.3%) 7 (23.3%)  
50-59 31 (34.4%) 5 (16.7%)  
>=60 9 (10.0%) /  
Weight (kg) 
(mean, range) 
78.5±15.5 (51-136) 75.9±14.1 (56-105)  
Height (cm) 
(mean, range) 
170.8±9.6 
(150-190) 
173.8±7.1 
(160-190) 
 
ABO blood type    
O+ 33 (36.7%) 13 (43.3%)  
O- 4 (4.4%) /  
A+ 25 (27.8%) 8 (26.7%)  
A- 3 (3.3%) /  
B+ 18 (20%) 3 (10.0%)  
B- 2 (2.2%) 3 (10.0%)  
AB+ 5 (5.6%) 1 (3.3%)  
AB- 1 (1.1%) 1 (3.3%)  
Parameters before 
mobilization (mean, 
range) 
   
WBC (x10
9
/l) 5.6±2.3 (1.9-14.1) 8.1±5.6 (3.9-29.1) p=0.001198 
Hgb (g/dl) 12.1±1.7 (8-15.5) 14.7±1.5 (11.8-18) p=0.000000 
Plt (x10
9
/l) 254±117.0 (78-649) 216±46.0 (130-306) NS 
Parameters before 
harvestration (mean, 
range)  
   
WBC (x10
9
/l) 21.5±12.6 (2.95-61.8) 29.6±8.2 (13.3-42.8) p=0.000170 
Hgb (g/dl) 12.0±1.3 (9.7-16) 14.4±1.5 (11.1-17.5) p=0.000000 
Plt (x10
9
/l) 167.9±95.0 (40-381) 201.2±61.2 (140-305) p=0.032651 
Hct (%) 36.0±4.3 (15.6-48) 43.6±3.9 (36.1-49.7) p=0.000000 
RBC (x10
9
/l) 3.9±0.5 (3.1-7.73) 4.8±0.4 (3.98-5.7) p=0.000000 
Monocytes (%) 9.7±4.9 (1.3-25.1) 5.4±2.4 (1.4-10.5) p=0.000001 
Lymphocytes (%) 12.2±6.1 (3.2-28.8) 11.8±3.5 (6.6-20.6) NS 
LymMon (%) 21.8±9.4 (7-53) 17.5±4.5 (10-26) p=0.027808 
Transfusion before 
harvestration (number 
of units, mean, range) 
   
Erythrocyte 
transfusion   
 
21 (23.3%) 
3.8±2.8 (1-11) 
/  
Platelet transfusion 
(RD) 
 
20 (22%) 
16.3±17.6 (1-66) 
/  
Platelet transfusion 
(SD) 
 
7 (7.8%) 
(1-2) 
/  
Mobilization strategy    
G-CSF 64 (71.1%) 30 (100%)  
G- 
 
CSF+chemotherapy 
26 (28.9%) /  
Adverse events    
Yes  14.4% 43.3% p=0.0009 
No  85.6% 56.7%  
RD – random donor, SD – single donor. 
 
Statistical analysis 
Statistical analysis was done in the statistical 
program Statistica 7.1 and SPSS 17.0. The following 
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methods were used in this study: the percentage of 
structure (%) was determined in series with attributive 
marks; descriptive statistics (Mean ± S.D., Minimum, 
Maximum, Median) was used in series with numerical 
marks; differences between the autologous and 
allogeneic donors in the parameters with attributive 
and numerical marks were tested with Mann-Whitney 
U test. The association between the investigated 
variables and the number of collected mononuclear 
cells (MNC) was assessed with Spearman rank order 
correlation. The accepted level of significance was p < 
0.05.  
 
 
Results 
 
Donors’ characteristics and laboratory 
parameters of autologous and allogeneic donors are 
shown in Table 1.  
Clinical characteristics of autologous donors 
are shown in Table 2.  
Table 2: Clinical characteristics of autologous donors 
Clinical characteristic of autologous donors Number (%) 
Diagnosis  
AML 30 (33.3%) 
MM 30 (33.3%) 
HD 19 (21.1%) 
NHL 11 (12.3%) 
Disease stadium  
CR 46 (51.1%) 
PR 23 (25.6%) 
Active disease (relapse) 21 (23.3%) 
Chemotherapy cycles  
0 / 
1-4 45 (50%) 
5-8 21 (23.3%) 
9-12 13 (14.4%) 
13-16 7 (7.8%) 
≥ 17 4 (4.4%) 
Previous radiotherapy and/or HSCT  
Radiotherapy+HSCT 2 (2.2%) 
Radiotherapy 12 (13.3%) 
HSCT 7 (7.8%) 
No radiotherapy and/or HSCT 69 (76.7%) 
Period from diagnosis to harvestration (months) – mean, 
range 
 
16.8 ± 27.8 (1-148) 
AML-acute myeloid leukemia, MM-multiple myeloma, HD-Hodgkin disease, NHL-non-
Hodgkin lymphoma, AA-aplastic anemia, ALL-acute lymphoblastic leukemia, MF-
myelofibrosis, CML-chronic myeloid leukemia, CR-complete remission, PR-partial 
remission, SCT-stem cell transplantation. 
 
There were 226 apheresis procedures, 182 
performed in 90 autologous donors and 44 
procedures performed in 30 allogeneic donors. The 
mean number of apheresis procedures in autologous 
donors was 2.0 ± 0.6 (range 1-3) and 1.5 ± 0.5 (range 
1-2) in allogeneic with significant difference between 
two of them (p < 0.05). Seventy six autologous donors 
(66.7%) had two apheresis procedures, sixteen 
autologous donors (17.7%) had three procedures and 
fourteen autologous donors (15.6%) had one 
procedure, while eight allogeneic donors (53.3%) had 
one procedure and twenty two allogeneic donors 
(46.7%) had two procedures. All donors tolerated well 
mobilization and collection procedures, with minor 
side effects in 14.4% of autologous and 43.3% 
allogeneic donors. The mean number of collected 
MNC in autologous donors was 3.09  1.1 (range 0.8-
6.2) and 3.23  1.03 (range 2.0-7.3) in allogeneic, 
respectively. There was not a statistically significant 
difference between the number of collected MNC in 
autologous and allogeneic donors for p>0.05 (Mann-
Whitney U test Z = -0.46364, p = 0.642909). The 
mean number of collected CD34+ cells in autologous 
donors was 2.85 ± 1.1 (range 0.7-5.9) and 3.20 ± 1.01 
(range 2.0-7.3) in allogeneic. There was not a 
statistically significant difference between the number 
of collected CD34+ cells in autologous and allogeneic 
donors for p > 0.05 (Mann-Whitney U test Z =               
-1.53091, p = 0.111631). Characteristics of PBSC 
collection are shown in Table 3.  
Table 3: Characteristics of PBSC collection 
Characteristics of PBSC collection Autologous donors Allogeneic donors 
No. of apheresis procedures 182 44 
No. of procedures per donor  2.0 1.5 
No. of donors collecting < 2х10
8
/kg MNC 13 (14.4%) / 
No. of donors collecting ≥ 2х10
8
/kg MNC 
 with 1 apheresis 
 with 2 apheresis 
 with 3 apheresis 
77 (85.6%) 
14 (15.6%) 
60 (66.7%) 
16 (17.7%) 
30 (100%) 
16 (53.3%) 
14 (46.7%) 
/ 
Type of set used for apheresis 
WBC set 
AutoPBSC 
 
34.1% 
65.9% 
 
22.7% 
77.3% 
No. of collected MNC х10
8
/kg - total 
(mean, range) 
 1 apheresis 
 2 apheresis 
 3 apheresis 
 
3.09 (0.8-6.2) 
1.7 (0.2-5.8) 
1.5 (0.14-3.9) 
1.1 (0.2-3.7) 
 
3.23 (2.0-7.3) 
2.4 (0.7-4.8) 
1.7 (0.4-5.0) 
/ 
No. of collected CD34+ cells х10
6
/kg – 
total (mean, range) 
 1 apheresis 
 2 apheresis 
 3 apheresis 
 
2.85 (0.7-5.9) 
1.6 (0.2-5.5) 
1.3 (0.14-3.7) 
1.0 (0.2-3.4) 
 
3.20 (2.0-7.3) 
2.3 (0.6-3.9) 
1.6 (0.4-4.8) 
/ 
Total processed volume (ml) 9475.6 9502.3 
 
All allogeneic donors (100%) and 77 (85.6%) 
autologous donors donated the wanted number of 
MNC and CD34+ cells. There were 13 autologous 
donors (14.4%) who could be marked as poor 
mobilizers, of which 11 donors (84.6%) had less than 
≤ 0.70 х 10
8
/kg MNC yield on the first day of 
harvestration (Table 4).  
Table 4: Number of collected MNC – 1 day yield and total 
number of collected MNC < 2 х 10
8
/kg 
Autologous donors 
Number of collected MNC 
– 1 day yield 
 
Number of 
donors 
 
 
% 
Total number of MNC < 
2х10
8
/kg 
Number of donors/(%) 
 ≤ 0.70 х 10
8
/kg 19 21.1 11 (84.6%) 
0.71-1.40 х 10
8
/kg 18 20.0 2 (15.4%) 
1.41-1.99 х 10
8
/kg 20 22.2 / 
2.00-2.99 х 10
8
/kg 21 23.3 / 
3.00-3.99 х 10
8
/kg 10 11.1 / 
≥ 4 х 10
8
/kg 2 2.2 / 
Allogeneic donors    
 ≤ 0.70 х 10
8
/kg 1 3.3 / 
0.71-1.40 х 10
8
/kg 5 16.7 / 
1.41-1.99 х 10
8
/kg 4 13.3 / 
2.00-2.99 х 10
8
/kg 12 40 / 
3.00-3.99 х 10
8
/kg 7 23.3 / 
 ≥ 4 х 10
8
/kg 1 3.3 / 
 
Poor mobilizers were defined as donors that 
could not donate ≥ 2 x 10
8
/kg MNC and/or ≥ 2 x 
10
6
/kg CD34+ cells in three consecutive 
harvestrations. Although Auto PBSC set was used in 
65.9% autologous and 77.3% allogeneic donors, 
significantly larger number of MNC and CD34+ cells 
was collected with WBC set. There was a statistically 
significant correlation between the total number of 
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collected MNC in autologous donors and baseline 
platelet count, the number of cycles in one apheresis 
procedure, quantity of collected graft and the number 
of MNC and CD34+ cells on the first day of 
harvestration (Table 5).  
Table 5: Correlation between investigated parameters and total 
number of collected MNC in autologous donors  
Total number of collected MNC Autologous 
donors 
Spearman t(N-2) p-level 
Age 0.091901 0.86577 0.388968 
Body weight/kg  -0.023559 -0.22106 0.825556 
Mobilization strategy -0.071293 -0.67049 0.504300 
Day of mobilization/beginning of harvestration -0.014276 -0.13393 0.893762 
Baseline Hgb (g/dl) 0.007265 0.06816 0.945814 
Baseline WBC (10
9
/l) 0.175445 1.67175 0.098126 
Baseline Plt (10
9
/l) 0.230993 2.22714 0.028490* 
Preapheresis WBC (10
9
/l) 0.164005 1.55962 0.122438 
Preapheresis Hct (%) -0.024281 -0.22785 0.820294 
Preapheresis Hgb (g/dl)  0.008486 0.07961 0.936732 
Preapheresis RBC (10
9
/l) 0.053234 0.50009 0.618258 
Preapheresis Plt (10
9
/l) 0.169979 1.61809 0.109222 
Preapheresis Lymphocytes (%)  0.105166 0.99204 0.323896 
Preapheresis Monocytes (%) 0.126103 1.19247 0.236283 
Preapheresis LymMon (%) 0.124428 1.17638 0.242616 
Type of set for apheresis  0.203019 1.94499 0.054969 
Total blood volume -0.045936 -0.43137 0.667251 
Number of apheresis procedures -0.158539 -1.50628 0.135576 
Number of cycles in one apheresis procedure 0.304611 3.00007 0.003510* 
Duration of harvestration (min) 0.083736 0.78829 0.432648 
Processed blood (ml)  -0.014854 -0.13935 0.889489 
Used АCD-А (ml)  0.054621 0.51316 0.609128 
Quantity of collected graft (ml)  0.270566 2.63647 0.009902* 
MNC (x10
8
/kg) – 1
st
 apheresis yield 0.524850 5.78426 0.000000* 
CD34+(x10
6
/kg) cells – 1
st
 apheresis yield 0.383858 3.89966 0.000188* 
Diagnosis 0.139693 1.32342 0.189125 
 
There was a statistically significant correlation 
between the total number of collected MNC in 
allogeneic donors and baseline platelet count, the 
number of cycles in one apheresis procedure, quantity 
of collected graft and the number of collected MNC on 
the first day of harvestration (Table 6).  
Table 6: Correlation between investigated parameters and total 
number of collected MNC in allogeneic donors 
Total number of collected MNC 
Allogeneic donors 
Spearman T (N-2) p-level 
Age 0.138293 0.73888 0.466130 
Body weight – donor -0.284884 -1.57263 0.127037 
Body weight – recipient -0.113395 -0.60393 0.550755 
Day of mobilization/beginning of 
harvestration 
-0.040943 -0.21683 0.829910 
Baseline Hgb (g/dl) -0.188177 -1.01385 0.319334 
Baseline WBC (10
9
/l) 0.053765 0.28491 0.777811 
Baseline Plt (10
9
/l) 0.366233 2.08261 0.046539* 
Preapheresis WBC (10
9
/l) 0.036352 0.19248 0.848754 
Preapheresis Hct (%) -0.211665 -1.14599 0.261498 
Preapheresis Hgb (g/dl) -0.077438 -0.41100 0.684202 
Preapheresis RBC (10
9
/l) -0.290003 -1.60346 0.120056 
Preapheresis Plt (10
9
/l)  0.337906 1.89978 0.067807 
Preapheresis Lym (%) -0.013612 -0.07203 0.943088 
Preapheresis Mon (%) -0.029668 -0.15706 0.876328 
Preapheresis LymMon (%) -0.106831 -0.56855 0.574193 
Total blood volume (ml) -0.234613 -1.27710 0.212057 
Number of apheresis procedures 0.100588 0.53498 0.596890 
Number of cycles in one apheresis 
procedure 
0.422963 2.46992 0.019873* 
Duration of harvestration (min) 0.174423 0.93733 0.356606 
Processed blood (ml) 0.009368 0.04957 0.960816 
Used ACD-A (ml) 0.066719 0.35383 0.726115 
Quantity of collected graft (ml) 0.522832 3.24548 0.003034* 
Adverse reactions 0.007790 0.04122 0.967412 
MNC (x10
8
/kg) – 1
st
 apheresis yield 0.403175 2.33128 0.027162* 
CD34+(x10
6
/kg) cells – 1
st
 apheresis yield 0.208007 1.12528 0.270022 
 
There was a strong correlation between the 
number of collected MNC and CD34+ cells on the first 
day of harvestration and the total number of collected 
MNC and CD34+ cells in poor mobilizers, and inverse 
correlation with the number of apheresis procedures. 
Donors that donated MNC ≤ 0.7 x 10
8
/kg and/or ≤ 0.7 
x 10
6
/kg CD34+ cells on the first harvest (84.6%) were 
strong predictors of poor mobilizers.  
 
  
Discussion 
 
There has been a lot of investigations of 
predictive factors that could influence mobilization and 
collection of PBSC in order to improve efficacy and 
safety of mobilization and harvestration [19-27]. There 
are still a lot of contradictory in the different studies 
that work on this issue and final conclusions cannot 
be made, primarily because of heterogeneity of the 
donors. Baseline platelet count, the number of 
apheresis cycles, quantity of collected graft and the 
number of collected MNC and/or CD34+ cells on the 
first day of apheresis were predictive factors for 
successful HSC collection in our study in both, 
autologous and allogeneic donors. These findings are 
with consistence with our previously published study 
[28]. Similar to our results, Suzuya et al. [4] found out 
that younger age, low body mass index, a high 
leukocyte count before mobilization, a high platelet 
count before and during mobilization and a low speed 
of withdrawal were associated with higher CD34+ cell 
yield in allogeneic donors. Corso et al. demonstrated 
that WBC count and platelet count correlated 
significantly with the number of CD34+ stem cell 
harvested [29]. Collection of stem cells based on the 
rising WBC and platelet count increases the number 
of CD34+ cells in leukapheresis product in 
comparison to collection on fixed day as shown by 
Krieger et al. [30]. Leucocyte count was the best 
predictor of collection efficacy of CD34+ cells in the 
studies of Ford et al. [31] and Verlinden et al [32], too. 
Ketterer et al. [33] reported that a platelet value higher 
than 150 x 10
9
/l correlated significantly with successful 
mobilization in patients with lymphoid malignancies. 
Zubair et al. showed that platelet count before growth 
factor administration significantly correlated with the 
total CD34+ cell yield (Spearman r = 0.38, p < 0.001). 
With a multiple linear regression model (adjusted R2 = 
0.31, AIC = 63.1), it has been determined that the 
baseline platelet count significantly correlated with 
total CD34+ cell yield in treated plasma cell disorder 
patients in their study [19]. Although there was no 
significant association between CD34+ cell × 10
6
/kg 
and blood parameters in the study of Garicoa et al., 
they found out that leukocyte count higher than 30 × 
10
9
/L and monocyte count higher than 1.8 × 10
9
/L 
could be predictive factors of efficient collection. 
However, these values cannot be considered absolute 
factors because patients with lower counts also had 
satisfactory collections [20]. Likewise to our study, 
some studies suggested [34, 35] that there was no 
correlation between the hematocrit and the wanted 
number of HSC, while another study showed inverse 
correlation between the two parameters [31]. Study of 
Mehta et al. [35], although did not show correlation 
between the wanted number of HSC and hematocrit in 
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autologous donors, pointed out that it would be 
favorable harvestration to start when hematocrit is at 
least 25-30%. Autologous donors are often anemic 
and there is a need for transfusion of blood 
components before harvestration, which is frequently 
the case with the platelets too, if their number is less 
than 30 x 10
9
/L [2]. Mobilizing strategy and the 
number of prior cytotoxic chemotherapy cycles had 
been reported to adversely affect the yield of PBSC in 
autologous donors in our [28] and some other studies 
[31, 36-38]. There had been a lot of other factors that 
had been investigated and similar results had been 
revealed. These investigations included gender [31, 
34], disease stadium [31], chemotherapy regimen 
[31], invasion of disease in bone marrow [31, 39], use 
of alkylating agents [40] and etc. Factors influencing 
apheresis procedure were investigated as well. Our 
study showed that the number of cycles in one 
apheresis procedure in autologous and allogeneic 
donors, and the type of set used in apheresis 
procedure in autologous donors, significantly 
influenced the collection of MNC and CD34+ cells. 
Zenga et al. [41] showed that number of collected 
MNC was positively correlated with the use of Auto 
PBSC set, while number of CD34+ cells was positively 
correlated with the use of WBC set in allogeneic 
donors. In other study [42], WBC set was superior to 
Auto PBSC set for collection of HSC in patients with 
multiple myeloma mobilized with G-CSF+ 
chemotherapy. One of the factors that did not show 
association with collection efficacy in our study, but 
had been presented in other studies as significant was 
processed volume of blood during apheresis [32, 34]. 
Ikeda et al. [39] found out in their study that mobilizing 
cytokines, timing of apheresis, characteristics of 
cellular separator and operative software influenced 
collection of HSC in autologous and allogeneic 
donors, while donor’s age and gender influenced the 
number of collected HSC in allogeneic donors. 
Pastore et al. showed that lower number of CD34+ 
cells on the first day of collection correlated with poor 
mobilizers in acute leukemia patients [36]. Donors that 
donated MNC ≤ 0.7 x 10
8
/kg and/or ≤ 0.7 x 10
6
/kg 
CD34+ cells on the first day of apheresis were strong 
predictors of poor mobilizers (84.6%) in our study. 
Similarly to our findings Duong et al. determined a cut 
point of ≤ 0.7 x 10
6
/kg CD34+ cells for the first day of 
apheresis as a predictor of inadequate CD34+ 
collection [43]. Early precise prediction of the 
likelihood of achieving adequate stem cell collection in 
autologous and allogeneic donors could prevent 
unsuccessful apheresis and permit appropriate 
mobilization alteration intended to improve collection 
of HSC. 
In conclusion, baseline platelet count might be 
considered as an accurate indicator of PBSC 
mobilization and collection in autologous and 
allogeneic donors. However, further studies should be 
conducted, including a larger number of donors in 
each group. Determining the proper level of 
preaheresis laboratory parameters for initiating 
mobilization and apheresis procedure which is safe for 
donors and greatly efficient in collection of PBSC is 
needed for optimization of these procedures, as well 
as for early intervention in poor mobilizers.  
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